Antithrombotic treatment in atrial fibrillation.
Atrial fibrillation (AF) is the most common sustained arrhythmia, that substantially increases morbidity and mortality. AF is gaining in clinical and economic importance, with stroke and thromboembolism being major complications. In this article, the evidence for AF treatment trial of antithrombotic therapy is reviewed. Stroke risk stratification of patients with AF is discussed, and practical recommendations for thromboprophylaxis are presented.
Lip
G Y H
GY
University Department of Medicine, City Hospital, Birmingham, UK. g.y.h.lip@bham.ac.uk
Boos
C J
CJ
D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology
D005343:Fibrinolytic Agents